Why the study?
The study was conducted to obtain new insight into the pathogenesis of skeletal muscle disease caused by the Gln147Pro substitution in beta-tropomyosin (Tpm2.2).
Key points are not available for this paper at this time.
Population
Single muscle fiber containing reconstituted thin filaments
Comparison
Gln147Pro substituted beta-tropomyosin vs wild-type during simulated stages of ATP hydrolysis
Design
In vitro polarized microfluorimetry study
Reveals mutation-driven filament changes; leaves open clinical translation or therapeutic targeting in Tpm2.2 myopathy.
We have used the technique of polarized microfluorimetry to obtain new insight into the pathogenesis of skeletal muscle disease caused by the Gln147Pro substitution in β-tropomyosin (Tpm2.2). The spatial rearrangements of actin, myosin and tropomyosin in the single muscle fiber containing reconstituted thin filaments were studied during simulation of several stages of ATP hydrolysis cycle. The angular orientation of the fluorescence probes bound to tropomyosin was found to be changed by the substitution and was characteristic for a shift of tropomyosin strands closer to the inner actin domains. It was observed both in the absence and in the presence of troponin, Ca2+ and myosin heads at all simulated stages of the ATPase cycle. The mutant showed higher flexibility. Moreover, the Gln147Pro substitution disrupted the myosin-induced displacement of tropomyosin over actin. The irregular positioning of the mutant tropomyosin caused premature activation of actin monomers and a tendency to increase the number of myosin cross-bridges in a state of strong binding with actin at low Ca2+.
No takes yet. Share an insight, caveat, or question.
Karpicheva et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: